Mersana Therapeutics, Inc. (MRSN)
Jan 6, 2026 - MRSN was delisted (reason: acquired by DAWN)
29.08
+0.04 (0.14%)
Inactive · Last trade price on Jan 5, 2026

Mersana Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Net Income
-70.08-69.19-171.67-204.21-170.06-88.05
Depreciation & Amortization
1.091.631.520.930.861.01
Stock-Based Compensation
9.2616.4621.1421.5218.417.17
Other Adjustments
3.58-0.5-1.12.082.550.06
Change in Receivables
--30-30--
Changes in Accounts Payable
0.36-2.86-6.080.950.480.94
Changes in Accrued Expenses
-3.81-2.93-20.9413.5912.577.28
Changes in Unearned Revenue
-12.51-23.88-22.14143.71-0.04-0.83
Changes in Other Operating Activities
-2.32-1.070.392.07-4.75-2.29
Operating Cash Flow
-74.37-82.34-168.88-49.36-139.99-74.7
Capital Expenditures
--0.13-2.17-2.2-0.65-0.47
Purchases of Investments
--133.43-155.92-247.52--
Proceeds from Sale of Investments
-145277.9797-37.5
Investing Cash Flow
77.7711.44119.88-152.72-0.6537.03
Long-Term Debt Issued
---0.15-24.04-
Long-Term Debt Repaid
-26.06-2.08---5.49-0.2
Net Long-Term Debt Issued (Repaid)
-26.06-2.08-0.15-18.56-0.2
Issuance of Common Stock
-6.3295.09153.2945.56230.73
Net Common Stock Issued (Repurchased)
-6.3295.09153.2945.56230.73
Other Financing Activities
-0.07-0.15-0.26-0.27-0.47-0.12
Financing Cash Flow
-25.874.0994.68153.0263.65230.41
Net Cash Flow
-22.48-66.8145.68-49.06-76.99192.74
Beginning Cash & Cash Equivalents
79.35175.04129.36178.43255.4262.67
Ending Cash & Cash Equivalents
56.87108.23175.04129.36178.43255.42
Free Cash Flow
-74.37-82.47-171.05-51.56-140.64-75.17
FCF Margin
-224.14%-203.65%-464.12%-193.97%-327060.47%-9078.38%
Free Cash Flow Per Share
-14.95-16.83-36.83-13.76-49.81-30.56
Levered Free Cash Flow
-113.34-100.52-221.23-45.16-143.04-82.6
Unlevered Free Cash Flow
-84.58-102.13-229.08-44.72-160.4-82.47
Updated Sep 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q